Omnicell Intrinsic Stock Value – OMNICELL to Announce Financial Results on Thursday
October 27, 2023
🌥️Trending News
OMNICELL ($NASDAQ:OMCL), a leading provider of medication and supply management solutions and adherence tools for healthcare systems and pharmacies, is set to announce their financial results on Thursday. OMNICELL helps improve safety, operational efficiency, and clinical performance in healthcare organizations across the globe. The company provides automated technologies such as medication adherence solutions, medication and supply management automation, pharmacy analytics, and inventory optimization. Their automated systems are designed to provide a secure and accurate system for handling medications and medical supplies.
They also provide detailed analytics and reporting to help healthcare organizations track usage data and optimize inventory management. With a strong commitment to customer service and innovative technology, OMNICELL is poised to continue delivering cutting-edge solutions to healthcare organizations across the globe.
Earnings
OMNICELL will be releasing its financial results for FY2023 Q2 on Thursday. The report will show that the company earned 272.74M USD in total revenue and 20.42M USD in net income from June 30 2021. This marks a 17.7% decrease in total revenue compared to the previous year, but a 125.1% increase in net income.
Over the last three years, OMNICELL has seen an increase in total revenue, reaching 298.97M USD. The company is optimistic that their financial performance will continue to improve in the coming quarters.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Omnicell. OMNICELL_to_Announce_Financial_Results_on_Thursday”>More…
| Total Revenues | Net Income | Net Margin |
| 1.24k | -23.18 | -1.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Omnicell. OMNICELL_to_Announce_Financial_Results_on_Thursday”>More…
| Operations | Investing | Financing |
| 189 | -61.58 | 20.08 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Omnicell. OMNICELL_to_Announce_Financial_Results_on_Thursday”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.19k | 1.03k | 25.34 |
Key Ratios Snapshot
Some of the financial key ratios for Omnicell are shown below. OMNICELL_to_Announce_Financial_Results_on_Thursday”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.9% | 26.3% | -2.8% |
| FCF Margin | ROE | ROA |
| 10.3% | -1.9% | -1.0% |
Price History
On the day, the OMNICELL stock opened at $35.7 and closed at $35.6, indicating a decrease of 0.4% from the previous closing price of $35.7. Investors and analysts will be closely watching these results to get an indication of the company’s performance in the current fiscal year. This announcement will be closely followed by investors and industry experts who have an interest in the stock. Live Quote…
Analysis – Omnicell Intrinsic Stock Value
GoodWhale recently analyzed the wellbeing of OMNICELL, and we arrived at a fair value of the OMNICELL share of around $115.6, using our proprietary Valuation Line. This was based on qualitative and quantitative data gathered from the company’s performance and financial statements. Interestingly, OMNICELL shares are now being traded at $35.6, which is undervalued by 69.2%. This indicates that there could be some great investment opportunities with the potential for strong returns for those who choose to invest in the company. More…
Peers
The company’s products are used by hospitals, nursing homes, home health agencies, and other healthcare providers. Omnicell Inc’s competitors include Nexus AG, PrimeCare Systems Inc, 10x Genomics Inc, and other companies that provide similar products and services.
– Nexus AG ($LTS:0FGL)
Nexus AG is a German software company that specializes in enterprise resource planning (ERP) software. The company has a market capitalization of 814.29 million euros as of 2022 and a return on equity of 11.21%. Nexus AG’s main competitors include SAP SE, Oracle Corporation, and Microsoft Corporation.
– PrimeCare Systems Inc ($OTCPK:PCYS)
PrimaCare Systems Inc is a publicly traded company with a market capitalization of $44.19 million as of March 2022. The company has a return on equity of 9.24%. PrimaCare Systems Inc is a healthcare technology company that provides software and services to healthcare providers.
– 10x Genomics Inc ($NASDAQ:TXG)
10x Genomics Inc is a life sciences company that develops and sells products and services for genomic analysis. The company’s products include sequencing services, software, and tools for analyzing genomic data. 10x Genomics was founded in 2012 and is headquartered in Pleasanton, California.
10x Genomics has a market cap of $3.07 billion as of 2022 and a return on equity of -10.81%. The company’s products are used for genomic sequencing and analysis, and its services include software and tools for analyzing genomic data. 10x Genomics was founded in 2012 and is headquartered in Pleasanton, California.
Summary
Investors will be closely watching Omnicell‘s upcoming earnings release on Thursday for clues about the company’s performance in the third quarter of the year. Recent news of new product launches suggests that revenue growth could be strong, while cost controls could lead to margin expansion. Analysts are forecasting solid year-over-year revenue growth, combined with a modest improvement in net income.
Investors will also be looking for commentary on the company’s strategic plans, including potential partnerships and acquisitions. Overall, Omnicell looks well-positioned to capitalize on its leadership position in the healthcare technology market, and investors should take note of the company’s performance in the upcoming earnings report.
